Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among …
Background In the USA, COVID-19 vaccines became available in mid-December, 2020,
with adults aged 65 years and older among the first groups prioritised for vaccination. We …
with adults aged 65 years and older among the first groups prioritised for vaccination. We …
First 12 patients with coronavirus disease 2019 (COVID-19) in the United States
…, MA Ben-Aderet, I Benowitz, H Biggs, AM Binder… - MedRxiv, 2020 - medrxiv.org
Introduction More than 93,000 cases of coronavirus disease (COVID-19) have been reported
worldwide. We describe the epidemiology, clinical course, and virologic characteristics of …
worldwide. We describe the epidemiology, clinical course, and virologic characteristics of …
Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis
AM Binder, J Adjemian, KN Olivier… - American journal of …, 2013 - atsjournals.org
Rationale: Persons with cystic fibrosis (CF) are at high risk of nontuberculous mycobacterial
(NTM) infection, with treatment requiring prolonged multidrug regimens that include …
(NTM) infection, with treatment requiring prolonged multidrug regimens that include …
[HTML][HTML] Human adenovirus surveillance—United States, 2003–2016
AM Binder - MMWR. Morbidity and mortality weekly report, 2017 - cdc.gov
Human adenoviruses (HAdVs) can cause a wide spectrum of clinical illness, ranging from
asymptomatic infections to severe illnesses and death. Approximately 60 HAdV genotypes …
asymptomatic infections to severe illnesses and death. Approximately 60 HAdV genotypes …
[HTML][HTML] Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia
…, AM Alkhamis, GR Abedi, X Lu, AM Binder… - Emerging infectious …, 2019 - ncbi.nlm.nih.gov
Middle East respiratory syndrome coronavirus (MERS-CoV) shedding and antibody responses
are not fully understood, particularly in relation to underlying medical conditions, clinical …
are not fully understood, particularly in relation to underlying medical conditions, clinical …
[HTML][HTML] Multifacility outbreak of middle east respiratory syndrome in Taif, Saudi Arabia
…, X Lu, DD Erdman, K Tatti, AM Binder… - Emerging infectious …, 2016 - ncbi.nlm.nih.gov
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is a novel respiratory
pathogen first reported in 2012. During September 2014–January 2015, an outbreak of 38 …
pathogen first reported in 2012. During September 2014–January 2015, an outbreak of 38 …
[HTML][HTML] Epidemiology and clinical features of Rocky Mountain spotted fever from enhanced surveillance, Sonora, Mexico: 2015–2018
…, E Ochoa-Mora, KN Heitman, AM Binder… - The American Journal …, 2021 - ncbi.nlm.nih.gov
Rocky Mountain spotted fever (RMSF), caused by Rickettsia rickettsii, is a severe and
potentially fatal tick-borne disease. In 2015, Mexico issued a declaration of epidemiologic …
potentially fatal tick-borne disease. In 2015, Mexico issued a declaration of epidemiologic …
A prospective cohort study in non-hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change over time
…, M Pomeroy, H Njuguna, G Fox, AM Binder… - … Diseases: An Official …, 2020 - ncbi.nlm.nih.gov
Background Improved understanding of SARS-CoV-2 spectrum of disease is essential for
clinical and public health interventions. There are limited data on mild or asymptomatic …
clinical and public health interventions. There are limited data on mild or asymptomatic …
[HTML][HTML] Diagnostic testing for galactose-alpha-1, 3-galactose, United States, 2010 to 2018
AM Binder, SP Commins, ML Altrich, T Wachs… - Annals of Allergy …, 2021 - Elsevier
Background Alpha-gal syndrome (AGS) is an emerging immunoglobulin E (IgE)–mediated
allergy to galactose-alpha-1,3-galactose (alpha-gal). The geographic distribution and burden …
allergy to galactose-alpha-1,3-galactose (alpha-gal). The geographic distribution and burden …
Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019
AM Binder, D Cherry‐Brown, BJ Biggerstaff, ES Jones… - Allergy, 2023 - Wiley Online Library
Background Alpha‐gal syndrome (AGS) is an IgE‐mediated allergy to galactose‐alpha‐1,3‐galactose.
Clinical presentation ranges from hives to anaphylaxis; episodes typically occur 2…
Clinical presentation ranges from hives to anaphylaxis; episodes typically occur 2…